RDD Blog » cancer

R&D Directions Insider

Archive for the ‘ cancer ’ Category

Molecular targeted therapy progress with lung cancer

Tuesday, July 5th, 2011

(This is a guest post from Sally Church, Ph.D, who writes the Pharma Strategy Blog. If you are on Twitter, follow her here.) In this second part of the ASCO report, we look at another area where significant strides are being made with molecular targeted therapy, lung cancer. For years, this ...

Posted in cancer, clinical trials, drug discovery | No Comments »

Personalized med prototype? Plexxikon discusses melanoma hopeful

Friday, March 4th, 2011

Plexxikon Inc., the small 45-person biotech in Northern California, made international news this week when big pharma Daiichi Sankyo, Japanâ€™s third-largest drugmaker, agreed to buy the company for as much as $935 million, enticed largely by Plexxikonâ€™s anticipated late-stage targeted drug, PLX4032, for advanced melanoma. By now, you likely know ...

Posted in cancer, clinical trials | No Comments »

Innovative delivery system gives boost to cancer vaccine development

Tuesday, January 25th, 2011

Development of a seal contraceptive has had a serendipitous result for one biotechnology company. Immunovaccine has begun making advances in cancer vaccine development through the use of its formulation system and DepoVax delivery technology. Cancer vaccines represent a multi-billion dollar market opportunity for pharmaceutical companies, but numerous vaccines fail clinical trials ...

Posted in cancer, clinical trials, vaccines | No Comments »

Co-development guidance sets road map, but hurdles remain

Tuesday, January 18th, 2011

You have about a month left to weigh in publicly, if so moved, on FDAâ€™s new draft guidance on the co-development of drugs designed for use in combination therapy. Deadline for written comments is Valentineâ€™s Day. The agency, in its guidelines released before the holidays, acknowledged the need for a ...

Posted in FDA, cancer, clinical trials, drug discovery | No Comments »

New field tackles cancer drug-heart risk connection

Friday, October 8th, 2010

The recent industry focus on cardiovascular adverse events has probably received the most attention around drugs for diabetes, but those concerns, experts are quick to remind, stretch across multiple therapeutic areas. Cancer has been one area where that discussion has been raised to new levels â€“ and, unfortunately, itâ€™s only ...

Posted in cancer | No Comments »

Wave of momentum for cancer immunotherapies

Friday, June 4th, 2010

Since the landmark approval of Provenge in late April for prostate cancer, much has been made of the significant buzz created for similar cancer immunotherapies (see stories here and here) that stimulate a patientâ€™s immune system to recognize, attack, and kill tumor cells. Clinical data for a new wave of ...

Posted in antibodies, cancer, clinical trials | No Comments »

Kareem news puts rare cancer in spotlight

Wednesday, November 18th, 2009

As a lifelong Philadelphia 76ers fan, I grew up rooting against Kareem Abdul-Jabbar. After all, the big, bad Lakers were always the one team blocking my beloved Sixers â€“ led by Dr. J and company â€“ from winning the NBA championship until â€œweâ€ finally broke through in 1983, sweeping L.A. ...

Posted in cancer, clinical trials | No Comments »

Palifosfamide lacks resistance, side effects of forebears

Monday, November 16th, 2009

Cancer drugs have come a long way and work very effectively today, but they create a tremendous expense for patients because treatment requires them to be admitted to the hospital. Drugs such as doxorubicin, ifosfamide, and cyclophosphamide can have severe side effects, including brain, kidney, and bladder issues, diminishing the ...

Posted in cancer, clinical trials | No Comments »

Acceleron looks past VEGF in cancer treatment

Friday, November 6th, 2009

Many cancer treatments being developed in the clinic focus on the VEGF pathway by blocking multiple kinase inhibitors or different proliferative agents simultaneously, which usually leads to serious side effects. But VEGF is just one piece of the tumor angiogenesis puzzle. Executives with Acceleron Pharma Inc. believe that a need exists ...

Posted in cancer, clinical trials | 1 Comment »

Progress made as search for breast cancer cure continues

Wednesday, October 7th, 2009

Since October is Breast Cancer Awareness Month, I thought it would be appropriate to bring attention to some recent news and findings in the field. A researcher from Northwestern University Feinberg School of Medicine has found a way to strengthen the breastâ€™s protective barriers to prevent cancer from metastasizing. The researcher found ...

Posted in cancer, clinical trials | No Comments »

©2013 UBM Canon